Aposcience AG assumes no responsibility or liability for any injury, loss or damage incurred as a result of any use or reliance upon the information and material contained within or downloaded from its website. Aposcience AG has taken considerable care in preparing information and materials which are displayed in its website. However, Aposcience AG is unable to provide any warranty concerning the accuracy or completeness of any information contained herein. Hypertext links to third party websites outside the Aposcience AG are provided for the convenience of users only. Aposcience AG is unable to provide any warranty concerning the accuracy or completeness of any information held within these third party websites – this is the responsibility of the publisher of the third party website. Furthermore, by linking to other websites, Aposcience AG in no way endorses the views or information held within such websites and is unable to grant permission to use material found on such sites.

Health Information
This website may contain information that is related to medical or health subjects. In this context, Aposcience AG explicitly points out that the corresponding indications do not substitute advice offered by a medical doctor, a pharmacist or other representatives of professions in the medical sector and that such information shall not be the basis for self-diagnosis or diagnosis by other persons. Aposcience AG advises in any case to consult a medical doctor. Scientific statements and information on the development of products or types of therapy always represent the state at the time of their first publication. Thus, they may be changed or modified in any kind, e.g., due to the results by progress of scientific research and technology.

All rights reserved by Aposcience AG. Copies of information on this website may be printed for personal use only. No part of this website (, may be reproduced or reused for any other purpose without prior written permission of Aposcience AG.

Latest News

Approval of DSMB for Lead In-Phase and Go-Ahead for MARSYAS II Main Study



Approval for clinical phase II study in DFU by German health agency PEI